HIGHLIGHTS
SUMMARY
Cancer cells have been shown to release aberrant glycan structures and glycoproteins in the bloodstream, where they can be detected and measured, particularly when tumour glycan epitopes involve tissue-specific proteins, such as aberrant circulating glycoforms of the prostate-specific antigen (PSA) in patients with prostate cancer. The authors leverage pre-treatment and on-treatment serum N-glycan profiles in 88 patients with advanced melanoma receiving ICI to identify novel glyco-markers of response to therapy and overall and progression-free survival. The green and magenta lines represent the performance resulting when the measured . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.